MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from issuance ofcommon stock upon...$1,376K Net cash provided by(used in) financing...$1,376K Net increase(decrease) in cash and cash...-$10,374K Canceled cashflow$1,376K Change in the fair valueof contingent...$2,066K Accounts payable$1,631K Stock basedcompensation$1,255K Change in fair value ofdebt, net$490K Depreciation andamortization$36K Right of use assets,operating leases and...-$27K Proceeds from maturitiesof investments$14,000K Net cash used inoperating activities-$9,928K Net cash provided byinvesting activities-$1,781K Canceled cashflow$5,505K Canceled cashflow$14,000K Effect of exchange ratechanges on cash-$41K Net loss-$13,442K Purchase of investments$15,707K Accrued expenses andother current...-$604K Other assets$486K Prepaid expenses andother current assets$374K Fair valueadjustment for warrants-$291K Amortization of discount onavailable-for-sale investments$236K Purchase of property andequipment$74K
Cash Flow
source: myfinsight.com

Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics, Inc. (QNCX)